Kala Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

KALA BIO

16/05/2022 14:32

* Kala Pharmaceuticals Inc  KALA.OQ  reported a quarterly
adjusted
loss of 45 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 36 cents per share.
    * Revenue fell 58% to $1.37 million from a year ago; 
analysts
expected $3.07 million. 
    * Kala Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 45 cents​.
    * The mean earnings estimate of analysts had risen by
about 12.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Kala Pharmaceuticals Inc shares had fallen by 50.5% this
quarter and lost 43.5% so far this year.
    * The company reported a quarterly loss of $32.94 million.
    * Wall Street's median 12-month price target for Kala
Pharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated May 16 at 01:32 p.m.  ​All
figures in US dollars unless otherwise stated